Sector News

Novartis, Siemens to develop blood tests for multiple sclerosis

September 23, 2020
Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline.

To start, the companies will design and develop a biomarker test aimed at neuroscience programs, and multiple sclerosis specifically—a treatment area that they expect to expand into a $23.5 billion global market by 2025.

The initial immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, which are linked to nerve cell injury and a variety of neurological conditions including MS.

Levels of neurofilament light chain in the blood have also been associated with various clinical measures of MS activity and MRI scans showing nerve damage. As a chronic inflammatory disease of the central nervous system, MS sees destruction of neurons’ protective myelin sheath across the brain, optic nerves and spinal cord.

In August, the FDA approved Novartis’ MS treatment Kesimpta for both the relapsing-remitting and secondary progressive forms of the disease. The drug, already approved in leukemia as Arzerra, targets particular immune system B cells expressing CD20.

Earlier this year, Novartis presented data for Mayzent, an S1P receptor modulator for secondary progressive MS, showing that early treatment could slow the course of the disease. However, in many cases, patients and doctors may not be aware that the disease has moved into the secondary progressive stage, and it is often diagnosed late as symptoms become more apparent.

“We are looking forward to our collaboration with Novartis as it promises to yield innovative diagnostic solutions to address critical unmet clinical needs,” said Deepak Nath, president of laboratory diagnostics for Siemens Healthineers.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.